Open, randomized, active-controlled insulin resistance outcome trial of safety and efficacy with empagliflozin in type 2 diabetic patients
Latest Information Update: 24 Sep 2020
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 23 Sep 2020 Status changed from active, no longer recruiting to completed.
- 23 Mar 2020 Planned End Date changed from 30 Sep 2018 to 31 Mar 2019.
- 21 Sep 2018 Planned End Date changed from 30 Jun 2018 to 30 Sep 2018.